Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs

Biagiotti, Sara; Rossi, Luigia; Bianchi, Marzia; Giacomini, Elisa; Pierigé, Francesca; Serafini, Giordano; Conaldi, Pier Giulio; Magnani, Mauro

doi:10.1016/j.jconrel.2011.05.024

Cited by 43 publications

(24 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2) [38,39]. Within the erythrocytes, tacrolimus is known to be highly associated with the FK-binding protein [40][41][42][43]. In the clinically unstable transplant patient, erythrocyte counts may highly fluctuate due to bleeding, red blood cell transfusions, dilution, bone marrow depression, and hemolysis due to extracorporeal equipment.…”

Section: Interpretation Of Whole-blood Tacrolimus Concentrations Earlmentioning

confidence: 99%

Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation

et al. 2019

View full text Add to dashboard Cite

The calcineurin inhibitor tacrolimus is an effective immunosuppressant and is extensively used in solid organ transplantation. In the first week after heart and lung transplantation, tacrolimus dosing is difficult due to considerable physiological changes because of clinical instability, and toxicity often occurs, even when tacrolimus concentrations are within the therapeutic range. The physiological and pharmacokinetic changes are outlined. Excessive variability in bioavailability may lead to higher interoccasion (dose-to-dose) variability than interindividual variability of pharmacokinetic parameters. Intravenous tacrolimus dosing may circumvent this high variability in bioavailability. Moreover, the interpretation of whole-blood concentrations is discussed. The unbound concentration is related to hematocrit, and changes in hematocrit may increase toxicity, even within the therapeutic range of whole-blood concentrations. Therefore, in clinically unstable patients with varying hematocrit, aiming at the lower therapeutic level is recommended and tacrolimus personalized dosing based on hematocrit-corrected whole-blood concentrations may be used to control the unbound tacrolimus plasma concentrations and subsequently reduce toxicity. Invited proposal CPKA-D-18-00212.

show abstract

Section: Interpretation Of Whole-blood Tacrolimus Concentrations Earlmentioning

confidence: 99%

Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Mica was purchased from Novascan Technologies, Inc. (Ames, Iowa, USA). The recombinant protein FKBP12 was already available in our lab where it had been characterized [11]. All other reagents and chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA).…”

Section: Chemicals and Reagentsmentioning

confidence: 99%

Label-free quantification of Tacrolimus in biological samples by atomic force microscopy

Menotta

Biagiotti

Streppa

et al. 2015

Analytica Chimica Acta

Self Cite

View full text Add to dashboard Cite

“…The idea that RBC can be used to entrap and transport diffusible drugs by binding to selected proteins was experimentally evaluated in our laboratories (43). Human FKBP12 and CypA were cloned and expressed as recombinant proteins in bacteria.…”

Section: The Immunophilin Family Of Proteinsmentioning

confidence: 99%

Drug delivery by red blood cells

et al. 2011

Self Cite

View full text Add to dashboard Cite

SummaryDrug delivery is a growing field of interdisciplinary activities that combine the use of new materials with the biochemical properties of selected drugs, with the aim of improving their therapeutic action and reducing their toxicity. In few cases, proper medical devices have been also realized to implement new drug delivery modalities. In this article, we have summarized available information and our experience on the use of autologous Red Blood Cells as carriers for drugs to be released within the vascular system. This is not a comprehensive review, but it focusses on the mechanisms that are available to distribute drugs in circulation by carrier red blood cells and provide illustrative examples on how this is currently obtained. We have not included a summary of clinical data collected in recent years using this technology but simply provided proper references for the interested readers. Finally, a special attention is devoted to the possibility of entrapping, into autologous red blood cells, recombinant drug-binding proteins. This new strategy is opening the way at a new modality to influence the vascular distribution of drugs by realizing a dynamic circulating container (the engineered red cell) capable of reversible binding and transportation of one or more drugs of interest selected on the bases of the red cell entrapped target proteins. This new modality is not yet fully developed and explored but will certainly provide a technical solution to the problem of stabilizing drug concentration in circulation improving drug efficacy and reducing drug toxicity.

show abstract

Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs

Cited by 43 publications

References 42 publications

Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation

Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation

Label-free quantification of Tacrolimus in biological samples by atomic force microscopy

Drug delivery by red blood cells

Contact Info

Product

Resources

About